NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the Company’s leadership team with the appointmen…
Author: Business Wire
Infectious Endophthalmitis (Ophthalmology) Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Infectious Endophthalmitis (Ophthalmology) – Drugs in Development, 2021” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information on the therapeutics under development for I…
Persistent Corneal Epithelial Defects Drugs Pipeline Landscape Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Persistent Corneal Epithelial Defects (Ophthalmology) – Drugs in Development, 2021” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information on the therapeutics under develo…
Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside conversation with Justin Kim, Exec…
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Raj Maturi, M…
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Warby Parker Announces Investor Day
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc., a founder-led direct-to-consumer lifestyle brand, today announced that it will hold an Investor Day Monday, September 13th. The pre-recorded event will be available beginning at 11 a.m. ET/8:00 a.m. PT. Reg…
Nimble Therapeutics Appoints Cyrus Arman, PhD, MBA as Chief Business Officer
MADISON, Wis.–(BUSINESS WIRE)–Nimble Therapeutics, an industry-leading peptide therapeutic discovery and optimization company, today announced the appointment of Dr. Cyrus Arman as Chief Business Officer. Cyrus will be responsible for structuring str…
U.S.Vision Announces New Partnership with Eyewear Brand, MITA
BLACKWOOD, N.J.–(BUSINESS WIRE)–U.S.Vision has partnered with Miami-based MITA Eyewear to become the exclusive distributor of the brand’s optical frame assortment.
Exegenesis Bio Opens Philadelphia and Boston Offices and Announces Expansion Plans
PHILADELPHIA–(BUSINESS WIRE)–Global gene therapy company announces plans to create up to 50 new jobs in Philadelphia and Boston. Launches next phase in global expansion.
NovaBay Pharmaceuticals to Present at the H.C. Wainwright 23nd Annual Global Investment Conference
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The company presentation w…
TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases
DENVER & CHICAGO–(BUSINESS WIRE)– #cancer–TriSalus Life Sciences announces the first patient enrolled in the PERIO-01 clinical trial for adults with uveal melanoma liver metastases.
Azura Ophthalmics Appoints Biopharma Industry Veteran Steven Altschuler, M.D. as Chair of the Board
TEL AVIV, Israel & MELBOURNE, Australia–(BUSINESS WIRE)–Azura Ophthalmics Ltd. today announced the appointment of Steven M. Altschuler, M.D., as chair of its board of directors.
Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today an…
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
Aerie Pharmaceuticals Announces Appointment of Michael Bradley, Senior Director, Manufacturing
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Global Juvenile Macular Degeneration Report on Drugs In Development, 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering. This report provides an overview of the Juvenile Macular Degenerat…
Color Blind Women Face Unique Challenges, EnChroma Study Finds
BERKELEY, Calif.–(BUSINESS WIRE)– #colorishere–Color Blind Women Face Unique Challenges, EnChroma Study Finds, Including Skepticism, Delayed Diagnoses; Feeling Excluded From Some Activities
Lancement d’une nouvelle série de vidéos pédagogiques : Dr Horus* décrypte de manière décalée les maladies de l’œil sur YouTube
SAINT-LAURENT DU VAR, France–(BUSINESS WIRE)–Les vidéos ludiques de Dr Horus sur YouTube ont pour objectif de vulgariser et de mieux faire connaître les maladies de l’œil.
La MHRA accorde le statut de Promising Innovative Medicine au Royaume-Uni à la thérapie génique LUMEVOQ® de GenSight Biologics
PARIS–(BUSINESS WIRE)–GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodégé…